BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

AAPG upcoming catalysts

Ascentage Pharma Group Inc.: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 4 readout(s) and 0 FDA event(s). Subscribe to AAPG (.ics).

Drugs: APG2575, lisaftoclax, BTK inhibitor, Toripalimab, pembrolizumab

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Ascentage Pharma Group Inc. AAPGNCT05147467 Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLChronic Lymphocytic Leukemia; Small Lymphocytic Lymphomarecruiting75
2026-12-31 est.P3Ascentage Pharma Group Inc. AAPGNCT06104566 Global Trial in APG2575 for Patients With CLL/SLLCLL/SLLrecruiting400

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-05-31 est.P2Ascentage Pharma Group Inc. AAPGNCT04496349 A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLT-Prolymphocytic Leukemia; Non-Hodgkins Lymphomarecruiting78
2026-04 est.P1/P2Ascentage Pharma Group Inc. AAPGNCT06182969 A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.SLErecruiting40
2026-04 est.P1/P2Ascentage Pharma Group Inc. AAPGNCT04785196 APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsLiposarcoma; Advanced Solid Tumorrecruiting95
2025-12-30 est.P1/P2Ascentage Pharma Group Inc. AAPGNCT03611868 A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsUnresectable or Metastatic Melanoma or Advanced Solid Tumors; Melanoma; Uveal Melanoma; P53 Mutationactive not recruiting230

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.